Early diagnosis, early isolation, and early treatment are efficient solutions to control the COVID-19 pandemic. To achieve the accurate early diagnosis of SARS-CoV-2, a multiplex detection strategy is required for the cross-validation to solve the problem of "false negative" of the existing gold standard assay. Here, we present a multicomponent nucleic acid assay platform for SARS-CoV-2 detection based on lanthanide nanoparticle (LnNP)-tagging strategy. For targeting SARS-CoV-2's RNA fragments ORF1ab gene, RdRp gene, and E gene, three LnNP probes can be used simultaneously to identify three sites in one sample through elemental mass spectrometry detection with limits of detection of 1.2, 1.3, and 1.3 fmol, respectively. With the multisite cross-validation, we envision that this multiplex and sensitive detection platform may provide an effective strategy for SARS-CoV-2 fast screening with a high accuracy.
Keyphrases
- sars cov
- nucleic acid
- real time pcr
- high throughput
- loop mediated isothermal amplification
- respiratory syndrome coronavirus
- sensitive detection
- mass spectrometry
- label free
- copy number
- genome wide
- high resolution
- gene expression
- single cell
- coronavirus disease
- quantum dots
- cancer therapy
- fluorescence imaging
- tandem mass spectrometry
- smoking cessation
- energy transfer
- gas chromatography
- combination therapy
- simultaneous determination
- silver nanoparticles